CA3092076A1 — Dosage forms and methods for enantiomerically enriched or pure bupropion
Assigned to Axsome Therapeutics Inc · Expires 2019-08-29 · 7y expired
What this patent protects
Use of enantiomerically enriched (S)-bupropion or a metabolite thereof in a dosage form. The (S)- bupropion in the dosage form may not be deuterium enriched. These dosage forms may be for oral administration to treat a condition, e.g. neuropsychiatric disorder, cold or cough, rel…
USPTO Abstract
Use of enantiomerically enriched (S)-bupropion or a metabolite thereof in a dosage form. The (S)- bupropion in the dosage form may not be deuterium enriched. These dosage forms may be for oral administration to treat a condition, e.g. neuropsychiatric disorder, cold or cough, relieving pain, addiction, or a condition that is treatable with (S)-bupropion, to achieve a certain plasma level or pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and/or to enhance dextromethorphan plasma levels. The use may include particular dosages and/or dosage frequencies.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.